Search

Your search keyword '"Chemnitz, Jens"' showing total 272 results
Start Over Author "Chemnitz, Jens"
272 results on '"Chemnitz, Jens"'

1. A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome

Author

Hamacher, Rainer, Liu, Xiaofei, Schuler, Markus K., Hentschel, Leopold, Schöffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars, Chemnitz, Jens-Markus, Crysandt, Martina, Stein, Alexander, Steffen, Björn, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Kunitz, Annegret, and Grünwald, Viktor

Published
2023
Full Text
View/download PDF

2. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Author

Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caillé, Léandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2021
Full Text
View/download PDF

5. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Author

Rautenberg, Christina, Stölzel, Friedrich, Röllig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Hänel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schäfer-Eckart, Kerstin, Schröder, Josephine, Kraus, Sabrina, Krüger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Röhnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Götze, Katharina S., Wagner-Drouet, Eva, Döhner, Konstanze, Döhner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhäuser, Martin, Germing, Ulrich, Schroeder, Thomas, and Middeke, Jan Moritz

Published
2021
Full Text
View/download PDF

10. Publisher Correction: Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection

Author

Beyer, Marc, Abdullah, Zeinab, Chemnitz, Jens M., Maisel, Daniela, Sander, Jil, Lehmann, Clara, Thabet, Yasser, Shinde, Prashant V., Schmidleithner, Lisa, Köhne, Maren, Trebicka, Jonel, Schierwagen, Robert, Hofmann, Andrea, Popov, Alexey, Lang, Karl S., Oxenius, Annette, Buch, Thorsten, Kurts, Christian, Heikenwalder, Mathias, Fätkenheuer, Gerd, Lang, Philipp A., Hartmann, Pia, Knolle, Percy A., and Schultze, Joachim L.

Published
2020
Full Text
View/download PDF

11. Transplantationsmedizin in der Intensivmedizin

Author

Michels, Guido, Ruhparwar, Arjang, Welte, Tobias, Gottlieb, Jens, Teschner, Sven, Burst, Volker, Mertens, Jessica, Stippel, Dirk, Herter-Sprie, Grit, von Bergwelt-Baildon, Michael, Theurich, Sebastian, Vehreschild, Janne, Scheid, Christoph, Chemnitz, Jens, Kochanek, Matthias, Michels, Guido, editor, and Kochanek, Matthias, editor

Published
2011
Full Text
View/download PDF

12. Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection

Author

Beyer, Marc, Abdullah, Zeinab, Chemnitz, Jens M, Maisel, Daniela, Sander, Jil, Lehmann, Clara, Thabet, Yasser, Shinde, Prashant V, Schmidleithner, Lisa, Köhne, Maren, Trebicka, Jonel, Schierwagen, Robert, Hofmann, Andrea, Popov, Alexey, Lang, Karl S, Oxenius, Annette, Buch, Thorsten, Kurts, Christian, Heikenwalder, Mathias, Fätkenheuer, Gerd, Lang, Philipp A, Hartmann, Pia, Knolle, Percy A, and Schultze, Joachim L

Published
2016
Full Text
View/download PDF

16. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation

Author

Holtick, Udo, Chemnitz, Jens-Markus, Shimabukuro-Vornhagen, Alexander, Theurich, Sebastian, Chakupurakal, Geothy, Krause, Anke, Fiedler, Anne, Luznik, Leo, Hellmich, Martin, Wolf, Dominik, Hallek, Michael, von Bergwelt-Baildon, Michael, and Scheid, Christof

Published
2016
Full Text
View/download PDF

18. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Author

Rautenberg, Christina, primary, Stölzel, Friedrich, additional, Röllig, Christoph, additional, Stelljes, Matthias, additional, Gaidzik, Verena I, additional, Lauseker, Michael, additional, Kriege, Oliver, additional, Verbeek, Mareike, additional, Unglaub, Julia M., additional, Thol, Felicitas, additional, Krause, Stefan W., additional, Haenel, Mathias, additional, Neuerburg, Charlotte, additional, Vucinic, Vladan, additional, Jehn, Christian, additional, Severmann, Julia, additional, Wass, Maxi, additional, Fransecky, Lars, additional, Chemnitz, Jens, additional, Holtick, Udo, additional, Schäfer-Eckart, Kerstin, additional, Schröder, Josephine, additional, Kraus, Sabrina, additional, Krüger, William Hermann, additional, Kaiser, Ulrich, additional, Scholl, Sebastian, additional, Henning, Lea, additional, Kobbe, Guido, additional, Haas, Rainer, additional, Alakel, Nael, additional, Röhnert, Maximilian Alexander, additional, Sockel, Katja, additional, Hanoun, Maher, additional, Platzbecker, Uwe, additional, Holderried, Tobias A. W., additional, Morgner, Anke, additional, Heuser, Michael, additional, Sauer, Tim, additional, Goetze, Katharina S., additional, Wagner, Eva Maria, additional, Döhner, Konstanze, additional, Döhner, Hartmut, additional, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Bornhäuser, Martin, additional, Germing, Ulrich, additional, Schroeder, Thomas, additional, and Middeke, Moritz Moritz, additional

Published
2021
Full Text
View/download PDF

21. Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Author

Liebers, Nora, Duell, Johannes, Nörenberg, Daniel, Kaebisch, Eva, Kerkhoff, Andrea, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan Moritz, Weber, Thomas, Trappe, Ralf Ulrich, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Gebauer, Niklas, Fuxius, Stefan, Caillé, Léandra, Pott, Christiane, Koenecke, Christian, Holtick, Udo, Geer, Thomas, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Hüttmann, Andreas, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2020
Full Text
View/download PDF

22. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., Thiede, Christian, Schulz-Abelius, Armin, Trepel, Martin, Teichmann, Martina, Kiani, Alexander, Glaß, Bertram, Görner, Martin, Behringer, Dirk, Kullmer, Johannes, Lamberti, Christof, Schmidt-Hieber, Martin, Flaßhove, Michael, MacKensen, Andreas, Hanoun, Maher, Kiehl, Michael, Höffkes, H.-G., Müller, Lutz Peter, Dürk, Heinz Albert, Held, Gerhard, Repp, Roland Peter, Baldus, Claudia, Chemnitz, Jens-Marcus, Klein, Stefan, Wilhelm, Martin, Schubert, Jörg, Meinhardt, Achim, Geer, Thomas, Ritter, Markus, Aulitzky, Walter Erich, and Heinz, Natalia

Subjects
Neuroblastoma RAS viral oncogene homolog, Oncology, musculoskeletal diseases, medicine.medical_specialty, NPM1, congenital, hereditary, and neonatal diseases and abnormalities, Medizin, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Context (language use), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Phosphoprotein Phosphatases, medicine, Humans, skin and connective tissue diseases, 030304 developmental biology, 0303 health sciences, Myeloid Neoplasia, business.industry, Remission Induction, Hazard ratio, Cytogenetics, Myeloid leukemia, Hematology, Odds ratio, Prognosis, 3. Good health, PTPN11, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, Mutation, business, Nucleophosmin
Abstract

The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11 mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11 mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11 mutations were associated with concomitant mutations in NPM1 (63%), DNMT3A (37%), and NRAS (21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P < .001) and higher white blood cell counts (P = .007) compared with PTPN11 wild-type patients. In a multivariable analysis, PTPN11 mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P < .001), relapse-free survival (HR: 1.52; P = .013), and a lower rate of complete remission (odds ratio: 0.46; P = .008). Importantly, the deleterious effect of PTPN11 mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11 mutations (HR: 2.28; P < .001) but not found with dominant PTPN11 mutations (HR: 1.07; P = .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11 mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.

Published
2021

23. Preinfection laboratory parameters may predict COVID‐19 severity in tumor patients

Author

Kiani, Alexander, primary, Roesch, Romina, additional, Wendtner, Clemens M., additional, Kullmann, Frank, additional, Kubin, Thomas, additional, Südhoff, Thomas, additional, Augustin, Marinela, additional, Schaich, Markus, additional, Müller‐Naendrup, Clemens, additional, Illerhaus, Gerald, additional, Hartmann, Frank, additional, Hebart, Holger, additional, Seggewiss‐Bernhardt, Ruth, additional, Bentz, Martin, additional, Späth‐Schwalbe, Ernst, additional, Reimer, Peter, additional, Kaiser, Ulrich, additional, Kapp, Markus, additional, Graeven, Ullrich, additional, Chemnitz, Jens‐Marcus, additional, Baesecke, Jörg, additional, Lambertz, Helmut, additional, and Naumann, Ralph, additional

Published
2021
Full Text
View/download PDF

24. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Author

Rautenberg, Christina, Stölzel, Friedrich, Röllig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Hänel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schäfer-Eckart, Kerstin, Schröder, Josephine, Kraus, Sabrina, Krüger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Röhnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Götze, Katharina S., Wagner-Drouet, Eva, Döhner, Konstanze, Döhner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhäuser, Martin, Germing, Ulrich, Schroeder, Thomas, and Middeke, Jan Moritz

Subjects
Article, Haematological cancer, Leukaemia, ddc
Published
2020

30. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

Author

Grünwald, Viktor, primary, Karch, Annika, additional, Schuler, Markus, additional, Schöffski, Patrick, additional, Kopp, Hans-Georg, additional, Bauer, Sebastian, additional, Kasper, Bernd, additional, Lindner, Lars H., additional, Chemnitz, Jens-Marcus, additional, Crysandt, Martina, additional, Stein, Alexander, additional, Steffen, Björn, additional, Richter, Stephan, additional, Egerer, Gerlinde, additional, Ivanyi, Philipp, additional, Zimmermann, Silke, additional, Liu, Xiaofei, additional, and Kunitz, Annegret, additional

Published
2020
Full Text
View/download PDF

31. Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)

Author

Hentschel, Leopold, primary, Richter, Stephan, additional, Kopp, Hans-Georg, additional, Kasper, Bernd, additional, Kunitz, Annegret, additional, Grünwald, Viktor, additional, Kessler, Torsten, additional, Chemnitz, Jens Marcus, additional, Pelzer, Uwe, additional, Schuler, Ulrich, additional, Freitag, Janet, additional, Schilling, Andrea, additional, Hornemann, Beate, additional, Arndt, Karin, additional, Bornhäuser, Martin, additional, and Schuler, Markus Kajo, additional

Published
2020
Full Text
View/download PDF

35. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

Author

Gruenwald, Viktor, Karch, Annika, Schuler, Markus, Schoeffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina, Stein, Alexander, Steffen, Bjoern, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Zimmermann, Silke, Liu, Xiaofei, Kunitz, Annegret, Gruenwald, Viktor, Karch, Annika, Schuler, Markus, Schoeffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina, Stein, Alexander, Steffen, Bjoern, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Zimmermann, Silke, Liu, Xiaofei, and Kunitz, Annegret

Abstract

PURPOSEDoxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity.PATIENTS AND METHODSPatients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m(2) once every 3 weeks (<= 6 cycles) after being randomly assigned in a 2:1 ratio. Noninferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% CI for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary end points. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient-reported outcomes. Cox regression analysis and Kaplan-Meier curves were used for analysis.RESULTSPazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. Overall survival did not differ significantly between arms (HR, 1.08; 95% CI, 0.68 to 1.72; P = .735). Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients.CONCLUSIONPazopanib was noninferior to doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. The distinct adverse event profile may be used to counsel patients and tailor therapy to indiv

Published
2020

37. Sequential therapy or patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience

Author

Ram, Ron, Scheid, Christof, Amit, Odelia, Chemnitz, Jens Markus, Moshe, Yakir, Hallek, Michael, Wolf, Dominik, Avivi, Irit, Holtick, Udo, Ram, Ron, Scheid, Christof, Amit, Odelia, Chemnitz, Jens Markus, Moshe, Yakir, Hallek, Michael, Wolf, Dominik, Avivi, Irit, and Holtick, Udo

Abstract

Primary refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The FLAMSA-reduced intensity conditioning protocol (total body irradiation or treosulfan-based) has been described as an effective approach in patients with refractory leukemia undergoing allogeneic hematopoietic cell transplantation. A modified protocol (without amsacrine) has also recently been used. We retrospectively analyzed the transplantation characteristics and outcomes of all consecutive patients between the years 2003 and 2017 (n=51) diagnosed with primary refractory AML who underwent transplantation at the University of Cologne and the Tel Aviv Medical Center. Median age was 54 years and median follow up was 37 months. Median time to neutrophil and platelet engraftment was 13 (range, 8-19) and 13 (range, 7-30) days, respectively. None of the patients had primary graft failure. Incidences of grade 2-4 and grade 3-4 acute graft-versus-host disease (GvHD), overall and moderate-severe chronic GvHD were 50% (95%CI: 41-67%), 12% (95%CI: 3-25%), 61% (95%CI: 47-72%), and 42% (95%CI: 34-51%), respectively. Anti-thymocyte globulin administration was associated with lower incidence of acute GvHD (FIR: 0.327; P=0.02). Non-relapse mortality at three months and three years were 6% and 16%, respectively. Relapse incidences were 6% and 29%, respectively. Overall survival rates at three months, three and five years were 90%, 61%, and 53%, respectively. Chronic GvHD disease was associated with a decreased mortality rate (HR 0.397; P=0.045). We conclude that sequential therapy in patients with primary refractory acute myeloid leukemia is safe and provides a remarkable anti-leukemic effect with durable survival and should be considered for every patient with primary refractory disease.

Published
2019

39. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).

Author

Grünwald, Viktor, primary, Kunitz, Annegret, additional, Schuler, Markus Kajo, additional, Schoffski, Patrick, additional, Kopp, Hans-Georg, additional, Bauer, Sebastian, additional, Kasper, Bernd, additional, Lindner, Lars H, additional, Chemnitz, Jens-Marcus, additional, Crysandt, Martina Margrit, additional, Stein, Alexander, additional, Steffen, Bjoern, additional, Egerer, Gerlinde, additional, Zimmermann, Silke, additional, and Karch, Annika, additional

Published
2018
Full Text
View/download PDF

40. Randomized phase II trial of trofosfamide vs. adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma.

Author

Hartmann, Joerg Thomas, primary, Kopp, Hans Georg, additional, Gruenwald, Viktor, additional, Piperno-Neumann, Sophie, additional, Kunitz, Annegret, additional, Hofheinz, Ralf, additional, Mueller, Lothar, additional, Geissler, Michael, additional, Horger, Marius, additional, Fix, Peter, additional, Chemnitz, Jens, additional, Eckert, Robert, additional, Hann von Weyhern, Claus, additional, Bauer, Sebastian, additional, and Mayer, Frank, additional

Published
2018
Full Text
View/download PDF

41. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).

Author

Grunwald, Viktor, Kunitz, Annegret, Schuler, Markus Kajo, Schoffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina Margrit, Stein, Alexander, Steffen, Bjoern, Egerer, Gerlinde, Zimmermann, Silke, Karch, Annika, Grunwald, Viktor, Kunitz, Annegret, Schuler, Markus Kajo, Schoffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina Margrit, Stein, Alexander, Steffen, Bjoern, Egerer, Gerlinde, Zimmermann, Silke, and Karch, Annika

Published
2018

42. Disseminated Neocosmospora vasinfecta Infection in a Patient with Acute Nonlymphocytic Leukemia

Author

Cornely, Oliver A., Chemnitz, Jens, Brochhagen, Hans-Georg, Lemmer, Karin, Schutt, Heidi, Sohngen, Dietmar, Staib, Peter, Wickenhauser, Claudia, Diehl, Volker, and Tintelnot, Kathrin

Subjects
Case studies, Pathogenic fungi -- Case studies, Myeloid leukemia -- Case studies, Fungi, Pathogenic -- Case studies, Myelocytic leukemia -- Case studies, Nonlymphoid leukemia -- Case studies
Abstract

We report Neocosmospora vasinfecta infection following chemotherapy for acute nonlymphocytic leukemia. N. vasinfecta, a plant pathogen, was identified by culture and genetic sequencing. Susceptibility testing revealed in vitro resistance for [...]

Published
2001

43. BKV Disease during the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation - Results of a Screening Program and Retrospective Analysis

Author

Posdzich, Philip, Herling, Marco, Leitzke, Silke, Hamacher, Laura, Di Christanziano, Veronica, Hoeller, Konstantin, Kaiser, Rolf, Chemnitz, Jens, Scheid, Christof, Holtick, Udo, Posdzich, Philip, Herling, Marco, Leitzke, Silke, Hamacher, Laura, Di Christanziano, Veronica, Hoeller, Konstantin, Kaiser, Rolf, Chemnitz, Jens, Scheid, Christof, and Holtick, Udo

Published
2016

44. BKV Disease during the First 100 Days after Allogeneic Hematopoietic Stem Cell Transplantation - Results of a Screening Program and Retrospective Analysis

Author

Posdzich, Philip, primary, Herling, Marco, additional, Leitzke, Silke, additional, Hamacher, Laura, additional, Di Christanziano, Veronica, additional, Hoeller, Konstantin, additional, Kaiser, Rolf, additional, Chemnitz, Jens, additional, Scheid, Christof, additional, and Holtick, Udo, additional

Published
2016
Full Text
View/download PDF

45. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML

Author

Holtick, Udo, primary, Herling, Marco, additional, Pflug, Natali, additional, Chakupurakal, Geothy, additional, Leitzke, Silke, additional, Wolf, Dominik, additional, Hallek, Michael, additional, Scheid, Christof, additional, and Chemnitz, Jens M., additional

Published
2016
Full Text
View/download PDF

46. CD4+T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation

Author

Holtick, Udo, Frenzel, Lukas P., Shimabukuro-Vornhagen, Alexander, Theurich, Sebastian, Claasen, Julia, Scheid, Christof, von Bergwelt-Baildon, Michael, Froehlich, Holger, Wendtner, Clemens M., Chemnitz, Jens M., Holtick, Udo, Frenzel, Lukas P., Shimabukuro-Vornhagen, Alexander, Theurich, Sebastian, Claasen, Julia, Scheid, Christof, von Bergwelt-Baildon, Michael, Froehlich, Holger, Wendtner, Clemens M., and Chemnitz, Jens M.

Abstract

The recovery of the host immune system after allogeneic hematopoietic stem cell transplantation is pivotal to prevent infections, relapse, and secondary malignancies. In particular, numerical CD4+ T cells reconstitution is delayed and CD4 helper cell function is considered impaired as a consequence of the transplant procedure and concomitant immunosuppressive medication. From HIV/AIDS patients, it is known that numerical and functional CD4 defects increase the risk of opportunistic infections. However, and in contrast to patients with HIV, anti-infective prophylaxis after allogeneic transplantation is usually given for 6 months depending on immunosuppressive medication and existing graft-versus-host disease but independently of absolute CD4+ T cells counts. We hypothesized that a qualitative T cell defect is existing after allogeneic transplantation, especially in patients with delayed immune-reconstitution. Applying transcriptional as well as functional approaches, we show that CD4+ T cells with delayed recovery have a distinct transcriptional profile and cluster differently from T cells originated from patients with completed immune recovery. Moreover, inhibitory signatures are substantially enriched within the transcriptional profile of these T cells translating to functional defects and impaired interleukin 2 production. In addition to time after transplant, CD4+ T cells numbers should be considered for the decision to stop or maintain antimicrobial prophylaxis in patients after allogeneic stem cell transplantation.

Published
2015

47. FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission

Author

Holtick, Udo, primary, Shimabukuro-Vornhagen, Alexander, additional, Chakupurakal, Geothy, additional, Theurich, Sebastian, additional, Leitzke, Silke, additional, Burst, Anke, additional, Hallek, Michael, additional, von Bergwelt-Baildon, Michael, additional, Scheid, Christof, additional, and Chemnitz, Jens M., additional

Published
2015
Full Text
View/download PDF

48. EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).

Author

Gruenwald, Viktor, primary, Kunitz, Annegret, additional, Schuler, Markus Kajo, additional, Kopp, Hans-Georg, additional, Kasper, Bernd, additional, Lindner, Lars, additional, Chemnitz, Jens-Marcus, additional, Stein, Alexander, additional, Schöffski, Patrick, additional, Steffen, Bjoern, additional, Bauer, Sebastian, additional, Egerer, Gerlinde, additional, Kneba, Michael, additional, Crysandt, Martina, additional, and Koch, Armin, additional

Published
2015
Full Text
View/download PDF

49. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation

Author

Holtick, Udo, primary, Chemnitz, Jens-Markus, additional, Shimabukuro-Vornhagen, Alexander, additional, Theurich, Sebastian, additional, Chakupurakal, Geothy, additional, Krause, Anke, additional, Fiedler, Anne, additional, Luznik, Leo, additional, Hellmich, Martin, additional, Wolf, Dominik, additional, Hallek, Michael, additional, von Bergwelt-Baildon, Michael, additional, and Scheid, Christof, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results